🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Enanta Pharmaceuticals, Inc. ENTA R2KR3KPHARMA

Healthcare · Biotechnology · United States
https://www.enanta.com
Company Profile ↓
$14.08
+56.44% 1Y
Mkt Cap$409.42M
P/E-5.42
P/B3.43
52W High$16.85
52W Low$7.17
Book Value$4.01
EPS (TTM)$-2.60

Company Overview

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Why Investors Should Care

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Sep 2025 Revenue of $65.32M (-3.4% YoY); net profit $-81.89M.
  • Trailing 12 Months Year-on-year growth — revenue +15.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR 3.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:3.23%
1 Year:15.00%

Stock Price Performance

1 Year:+56.44%
6 Months:+3.99%
3 Months:+24.82%
1 Month:+5.55%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 71% of range
$7.17 $16.85
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)57.31 · Neutral
Price Performance
1M+5.55%
3M+24.82%
6M+3.99%
1Y+56.44%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-5.42
Industry PE
25.17
Forward P/E
-6.88
PEG Ratio
-
Book Value
$4.01
Price to Book
3.43
P/S
5.79
EV/EBITDA
-7.63
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
3.23%
Profit 5Y
-
Revenue (YoY)
15.00%
Earnings (YoY)
-

Profitability & Returns

ROCE
-36.76%
ROE
-59.00%
ROA
-11.84%
Profit Margin
-89.55%
Op Margin
-69.07%
Gross Margin
100.00%
EPS (Latest Qtr)
$-0.45
EPS (TTM)
$-2.60

Balance Sheet & Liquidity

Debt/Equity
1.60
Quick Ratio
3.69
Current Ratio
3.84
Debt
$186.62M
Total Assets
$314.70M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
4.67%
Chg in Prom Hold
-0.01%
FII / Inst Holding
94.33%
Chg in FII Hold
-0.04%

Financial Snapshot

Enterprise Value
$409.42M
Total Revenue (TTM)
$69.21M
EBITDA
$-55.45M
Free Cash Flow
$7.69M
Operating Cash Flow
$-7.84M
Shares Outstanding
29.08M
Gross Margin
100.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ENTA Enanta Pharmaceuticals, Inc. R2KR3KPHARMA 14.08 -5.42 $409.42M 0.00% -36.76% -59.00% 3.23% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Dec 2021Mar 2022Jun 2022Dec 2022Mar 2023Jun 2023Dec 2023Mar 2024Jun 2024Dec 2024Mar 2025Jun 2025Dec 2025Mar 2026
Revenue -------10.42M8.96M7.51M75.93M38.11M44.05M57.26M67.20M69.89M39.63M44.37M51.31M52.57M27.62M18.65M23.63M31.74M20.13M21.62M27.65M18.72M19.48M23.59M17.80M18.89M18.00M17.05M17.97M16.96M14.93M18.31M18.61M17.16M
Operating Income 48.56M1.70M-35.59M-565.00K-1.09M--7.05M-9.51M-13.13M-14.38M16.86M22.64M-27.86M-1.30M3.75M-12.87M-11.88M-22.85M--12.30M-29.70M-33.85M-30.41M-33.85M-32.54M-30.01M-39.45M-36.71M-34.89M-32.77M-24.18M-23.54M-24.53M-18.89M-11.25M-11.85M
Net Income 28.75M2.42M5.81M26.19M-1.65M-1.08M-1.80M-4.98M-5.39M-8.43M36.51M11.69M12.55M20.29M27.42M26.01M4.14M7.04M9.19M13.44M-6.00M-14.27M-29.34M-8.33M-22.05M-24.02M-30.11M-33.59M-31.70M-28.99M-37.66M-39.06M-33.41M-31.16M-22.66M-22.29M-22.64M-18.25M-11.94M-13.09M
Diluted EPS 1.490.130.291.37-0.09-0.06-0.09-0.26-0.28-0.441.860.590.610.971.301.250.200.330.440.65-0.30-0.71-1.46-0.41-1.09-1.19-1.48-1.63-1.53-1.39-1.79-1.86-1.58-1.47-1.07-1.05-1.06-0.85-0.42-0.45
R&D Expense 5.37M6.25M-9.03M9.14M10.79M-12.53M13.00M15.41M-17.96M21.48M28.49M-34.88M34.16M34.46M-32.78M32.61M34.68M-36.66M41.51M46.99M48.55M42.09M39.09M40.90M43.47M42.99M36.37M35.59M28.74M27.66M28.07M27.21M20.86M19.44M

Profit & Loss (Annual)

Figures in USD.

Metric Sep 2011Sep 2012Sep 2013Sep 2014Sep 2015Sep 2016Sep 2017Sep 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Revenue 41.88M41.71M32.05M47.74M160.88M88.27M102.81M206.62M205.20M122.47M97.07M86.16M79.20M67.64M65.32M
Operating Income 25.30M21.29M9.03M18.98M124.15M30.84M24.61M88.33M36.74M-41.64M-109.57M-123.84M-137.21M-121.69M-85.35M
Net Income 23.31M21.40M9.63M34.44M78.99M21.67M17.71M71.96M46.38M-36.17M-79.00M-121.75M-133.82M-116.05M-81.89M
Diluted EPS 1.321.13-0.671.804.091.130.913.482.21-1.81-3.92-5.91-6.38-5.48-3.84
R&D Expense 11.55M15.12M16.84M18.74M23.19M40.46M57.45M94.86M142.21M136.76M174.11M164.52M163.52M131.48M106.74M

Balance Sheet (Annual)

Figures in USD.

Metric Sep 2010Sep 2011Sep 2012Sep 2013Sep 2014Sep 2015Sep 2016Sep 2017Sep 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Total Assets --52.16M116.97M155.41M246.01M281.28M326.64M414.23M489.83M486.13M438.79M375.41M462.27M376.65M280.73M
Total Equity -150.07M-131.96M-115.35M110.47M148.65M236.16M269.94M301.68M393.68M462.49M455.58M399.43M321.33M216.74M128.81M64.72M
Cash & Equivalents 466.00K6.84M10.51M8.86M30.70M21.73M16.58M65.67M63.90M51.23M87.13M57.21M43.99M85.39M37.23M32.30M
Total Liabilities --8.23M6.50M6.76M9.86M11.34M24.96M20.55M27.34M30.55M39.36M54.08M245.54M247.84M216.01M
Current Liabilities --5.73M4.53M4.75M6.70M7.89M20.98M16.02M22.61M24.16M36.17M29.83M62.79M57.53M48.55M

Cash Flows (Annual)

Figures in USD.

Metric Sep 2011Sep 2012Sep 2013Sep 2014Sep 2015Sep 2016Sep 2017Sep 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Operating Cash Flow 24.02M22.62M10.65M--35.81M52.65M29.22M71.42M7.09M-70.00M-84.78M-103.15M-78.76M-19.27M
Investing Cash Flow -17.68M-18.04M-69.22M---43.66M-4.57M-35.40M-86.66M19.83M36.99M54.90M-53.58M58.23M40.35M
Financing Cash Flow 34.00K-909.00K56.91M--2.71M1.02M4.41M2.57M8.98M3.08M20.03M198.13M-27.63M-26.62M
Capital Expenditure -445.00K-252.00K-606.00K-1.03M-2.34M-4.74M-2.51M-2.98M-5.42M-1.45M-750.00K-2.12M-9.06M-17.95M-12.90M
Free Cash Flow 23.57M22.37M10.05M--31.07M50.15M26.24M66.00M5.64M-70.75M-86.91M-112.21M-96.71M-32.17M

Ratios (Annual)

Figures in %.

Metric Sep 2011Sep 2012Sep 2013Sep 2014Sep 2015Sep 2016Sep 2017Sep 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Gross Margin % ---------------
Operating Margin % 60.4%51.0%28.2%39.8%77.2%34.9%23.9%42.7%17.9%-34.0%-112.9%-143.7%-173.2%-179.9%-130.7%
Net Margin % 55.7%51.3%30.0%72.1%49.1%24.5%17.2%34.8%22.6%-29.5%-81.4%-141.3%-169.0%-171.6%-125.4%
ROE % -17.7%-18.6%8.7%23.2%33.4%8.0%5.9%18.3%10.0%-7.9%-19.8%-37.9%-61.7%-90.1%-126.5%
ROCE % -45.9%8.0%12.6%51.9%11.3%8.1%22.2%7.9%-9.0%-27.2%-35.8%-34.3%-38.1%-36.8%

Shareholding Pattern

Insiders
4.67%
Institutions
94.33%
Public Float
98.95%

Top Institutional Holders

#Holder% HeldSharesValue
1 Jupiter Topco LLC 12.55% 3.65M $49.71M
2 Blackrock Inc. 11.14% 3.24M $44.12M
3 Krensavage Asset Management, LLC 9.84% 2.87M $38.98M
4 Farallon Capital Management LLC 8.30% 2.42M $32.89M
5 Deep Track Capital, Lp 4.96% 1.44M $19.64M
6 Adar1 Capital Management, LLC 4.62% 1.34M $18.29M
7 Vanguard Capital Management LLC 4.16% 1.21M $16.48M
8 Spruce Street Capital LP 3.74% 1.09M $14.81M
9 Acadian Asset Management. LLC 3.70% 1.08M $14.67M
10 Vanguard Portfolio Management LLC 3.47% 1.01M $13.76M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ENTA

Google News ue, 01 Sep 2026

Two talks by Enanta Pharmaceuticals are scheduled for Sept. 15 and 16. Both will be webcast live. - Stock Titan

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNbERLQk5la0VhdkVaWGJXaVBETjRCeEl2VFNkOTM5NGZsbkJvbEdwd29jWUh6TXR3d3NsTEFIWHVUTXBQWDFrX0ZLUzRwM3BKRENvSEZ1d3Nhb2VDNnJOTFBDRE1wZWYtNW1nb3lnVWVHUHZ0Y0lpd3UzYmY0UmJQbHdWU29uTVhXTmVScz…

Google News Sun, 06 Sep 2026

(ENTA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQRm54bHE5TUJiRE9NR2MyTHlrVzRmVUNtRnhfcHFMMFFOY1p5UG1tUjBzeXFsd2lsSmRZdGYtc1h3WEw3bVdtVm1uMTdqU0lvZzUyeTVVd19FV09FanVPMUs5RVdRcnVMMDcwdHA2cFkxTzBlTUlNQWhBUm5ESUg1VjE4M1paRW4wRkFuS3…

Google News Wed, 24 Jun 2026

Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPOVV5cjlXMFpBM0J1TFR6NUN5QXRTMUdNSVBFVnk2czNweERhc0NTT3hqX3FmSnJWdTQwUk4tMWREa3QxTmxNQWlKV0ZRZGo2cmM3RXdtemlyczZaN0l3dF9pS3JXdFJzcEhYQVpiOVJhUW1MWmdiOE5IU25QU1NqanNCTTgwOHlqQUVOS3…

Google News ue, 11 Aug 2026

Enanta Pharmaceuticals (ENTA) Stock Faces Revenue Slip And Wider Losses - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPcnJBY0UtUVhiMjA3dGhLMWxub01Xemc4dlFtMWdZTkdvV0ZZQndZR0xLRDN3eGltWkpfWjc5cFhBVUQ0LVppMzhLRGRmQUFLTU42LW1Nem96YUljYTJRLXVpbmNWTU5aTm1LVmNfMEFlRUFQLXhoOVp6TUFBNEJ1T3ZiZFZvZTZWdkJWQ2…

Google News Wed, 27 May 2026

ENTA - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9DSkFBdnhNR1NPcE56OEpmb19GMktUUGRmRTNzVi1sMzZMY2t4OTRsUTEzMC1BQjA2ZnNvajZGNXQ5RWFqbGc?oc=5" target="_blank">ENTA</a>&nbsp;&nbsp;<font color="#6f6f6f">Finviz</font>…

Google News hu, 25 Jun 2026

ENTA Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBzR3ZHUkRLOXJmSW4zSHFzNklKQ0ZZM1FMeDZaUUdCU01DQndKeGd5dThmRy1xVERBd3dZREQ3MFp2cmpERHBhWGtseV91Vk1OUEZieG5oNjBEWExyQ3QxcW1JTzlWNk80M1hrQnA4T0xEYzY2NEtONFF3?oc=5" target="_blank">ENT…

ENTA — Frequently Asked Questions

What is the current share price of Enanta Pharmaceuticals, Inc. (ENTA)?

As of 2026-09-07 16:24 PDT, Enanta Pharmaceuticals, Inc. (ENTA) trades at $14.08 on NasdaqGS. Its 52-week range is $7.17 to $16.85.

What is the market capitalisation of ENTA?

Enanta Pharmaceuticals, Inc. (ENTA) has a market capitalisation of $409.42M on NasdaqGS.

What is the P/E ratio of ENTA?

ENTA trades at a trailing price-to-earnings (P/E) ratio of -5.42. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.43.

What is the return on equity (ROE) of ENTA?

ENTA has a return on equity (ROE) of -59.00%. Its return on capital employed (ROCE) is -36.76%.

Is ENTA a good stock to buy?

This page provides a data-driven analysis of Enanta Pharmaceuticals, Inc. (ENTA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space